Philips Clinical & Medical Affairs Global
Trial Pipeline
Respiration From Pleth Validation
NCT07449715
SPO2 VALIDATION STUDY - PHILIPS FAST 2025
NCT07221526
The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial (Cardiac Output Study)
NCT06895603
The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial
NCT06895590
Radiation Free Study
NCT06549348
RADIQAL Study (Radiation Dose and Image Quality Trial)
NCT06944509
The THOR IDE Study
NCT05916950
Project Mountain - Comparing SpO2 and SaO2 for Accuracy
NCT06372106
NIBP Validation Study
NCT05673408
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
NCT04701684
HeartStart HS1 Defibrillator* Event Registry
NCT04840797
HeartStart FRx Defibrillator Event Registry
NCT04250857
The Intrepid Clinical Engineering Study
NCT05636332
Vector Engineering Clinical
NCT04725500
Therapeutic Areas
What the Pipeline for Philips Clinical & Medical Affairs Global Shows
According to the ClinicalTrials.gov registry, Philips Clinical & Medical Affairs Global is linked to 186 US clinical trials across every stage of research activity. Of those, 184 studies are currently recruiting — about 99% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 1% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Philips Clinical & Medical Affairs Global reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Philips Clinical & Medical Affairs Global is Sudden Cardiac Arrest with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.